Descending aortic calcification increases renal dysfunction and in-hospital mortality in cardiac surgery patients with intraaortic balloon pump counterpulsation placed perioperatively : a case control study by Nowak-Machen, Martina et al.
RESEARCH Open Access
Descending aortic calcification increases renal
dysfunction and in-hospital mortality in cardiac
surgery patients with intraaortic balloon pump
counterpulsation placed perioperatively: a case
control study
Martina Nowak-Machen
1, James D Rawn
2, Prem S Shekar
2, Aya Mitani
3, Sagun Tuli
4, Tobias M Bingold
7,
Garrett Lawlor
5, Holger K Eltzschig
6, Stanton K Shernan
1 and Peter Rosenberger
7,8*
Abstract
Introduction: Acute kidney injury (AKI) after cardiac surgery increases length of hospital stay and in-hospital
mortality. A significant number of patients undergoing cardiac surgical procedures require perioperative intra-aortic
balloon pump (IABP) support. Use of an IABP has been linked to an increased incidence of perioperative renal
dysfunction and death. This might be due to dislodgement of atherosclerotic material in the descending thoracic
aorta (DTA). Therefore, we retrospectively studied the correlation between DTA atheroma, AKI and in-hospital
mortality.
Methods: A total of 454 patients were retrospectively matched to one of four groups: -IABP/-DTA atheroma,
+IABP/-DTA atheroma, -IABP/+DTA atheroma, +IABP/+DTA atheroma. Patients were then matched according to
presence/absence of DTA atheroma, presence/absence of IABP, performed surgical procedure, age, gender and left
ventricular ejection fraction (LVEF). DTA atheroma was assessed through standard transesophageal
echocardiography (TEE) imaging studies of the descending thoracic aorta.
Results: Basic patient characteristics, except for age and gender, did not differ between groups. Perioperative AKI
in patients with -DTA atheroma/+IABP was 5.1% versus 1.7% in patients with -DTA atheroma/-IABP. In patients with
+DTA atheroma/+IABP the incidence of AKI was 12.6% versus 5.1% in patients with +DTA atheroma/-IABP. In-
hospital mortality in patients with +DTA atheroma/-IABP was 3.4% versus 8.4% with +DTA atheroma/+IABP. In
patients with +DTA atheroma/+IABP in hospital mortality was 20.2% versus 6.4% with +DTA atheroma/-IABP.
Multivariate logistic regression identified DTA atheroma > 1 mm (P = *0.002, odds ratio (OR) = 4.13, confidence
interval (CI) = 1.66 to 10.30), as well as IABP support (P = *0.015, OR = 3.04, CI = 1.24 to 7.45) as independent
predictors of perioperative AKI and increased in-hospital mortality. DTA atheroma in conjunction with IABP
significantly increased the risk of developing acute kidney injury (P = 0.0016) and in-hospital mortality (P = 0.0001)
when compared to control subjects without IABP and without DTA atheroma.
Conclusions: Perioperative IABP and DTA atheroma are independent predictors of perioperative AKI and in-
hospital mortality. Whether adding an IABP in patients with severe DTA calcification increases their risk of
developing AKI and mortality postoperatively cannot be clearly answered in this study. Nevertheless, when IABP
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Introduction
Acute kidney injury (AKI) represents one of the most
detrimental complications after open heart surgery. The
incidence of perioperative AKI has been reported to vary
from 1% to 30%. Patients developing AKI are at higher
risk for an extended hospital stay and for increased in-
hospital mortality [1-3]. Several preoperative risk factors
for AKI are known including medical conditions such as
diabetes mellitus, congestive heart failure (CHF) or
increased age. Patients with CHF, acute coronary syn-
drome (ACS) or inability to be weaned off cardiopulmon-
ary bypass (CPB) are often treated with intra-aortic
balloon counterpulsation (IABP). IABP support has pre-
viously been linked to the development of postoperative
renal dysfunction [4-10].
The etiology of AKI following cardiopulmonary bypass
and during IABP support remains poorly understood. In
rare cases the development of AKI during IABP support
can be explained by displacement of the IABP and subse-
quent occlusion of the renal arteries. To date, it remains
controversial if a calcified descending thoracic aorta
(DTA) could increase the incidence of AKI in patients
with IABP through possible dislodgement of embolic
material. However, IABP support as well as DTA ather-
oma has been linked independently to the development
of postoperative AKI [4-10]. A displacement of aortic
microemboli triggered by mechanical forces applied to
the aortic wall during the use of IABP counterpulsation
with subsequent impairment of the renal circulation
seems possible. Intraoperative transesophageal echocar-
diography (TEE) is an excellent tool to monitor for the
presence of aortic atheroma during cardiac surgery
[11-14]. TEE is also readily available in most medical cen-
ters and is helpful for the identification of descending
aortic atheroma.
To date, an association between the occurrence of AKI
with the combination of DTA atheroma and/or the use
of an IABP has not been well investigated. Given the
importance of this for the length of in-hospital stay and
in-hospital mortality we hypothesized that IABP counter-
pulsation in patients with DTA would lead to an
increased incidence of perioperative AKI and in-hospital
mortality following cardiac surgery.
In this study we confirm that DTA atheroma and IABP
independently increase the risk for acute kidney injury and
in-hospital mortality. We also report that the combination
of DTA atheroma and IABP further increases the inci-
dence of acute kidney injury and in-hospital mortality.
Materials and methods
Study design and matching
Approval for this retrospective case control study was
obtained from the Institutional Review Board (IRB) of
the Brigham and Women’s Hospital/Harvard Medical
School. Written informed consent was waived for this
retrospective study.
A total of 454 patients, 50 years old and older (mean ±
68 years) with normal renal function preoperatively (crea-
tinine < 1.5 mg/dL), who had undergone heart surgery at
Brigham and Women’s Hospital between January 1995
and December 2005 were retrospectively evaluated. Out of
those patients we selected all patients who had received an
IABP within 24 hours prior to or during surgery. Patients
with preoperative renal insufficiency (creatinine ≥1.5 mg/
dl) and TEE imaging-windows which were inadequate to
demonstrate the severity of DTA atheroma, as well as
patients who received IABP support after leaving the oper-
ating room, were excluded from the study population.
Matching for the remaining 454 patients was then
attempted according to the degree of DTA atheroma, per-
formed surgical procedure, age, gender and left ventricular
ejection fraction (LVEF) to one of four groups: -IABP/-
DTA atheroma, +IABP/-DTA atheroma, -IABP/+DTA
atheroma, +IABP/+DTA atheroma. Patients with DTA
atheroma were slightly older and less likely to be male.
Definition of preoperative medical co-morbidities
Demographics and historical data were obtained from the
computerized institutional database and included age, gen-
der, history of hypertension necessitating treatment with
antihypertensive medications, diabetes mellitus, congestive
heart failure, hypercholesterolemia, medications including
Angiotensin-converting ezyme (ACE) -inhibitors, Aspirin
(ASA) and 3-hydroxy-3-methyl-glutaryl (HMG) -CoA
reductase inhibitors and use of aminocaprioc acid or apro-
tinin during surgery. Preoperative co-morbidities were
defined according to the Society of Thoracic Surgeons
(STS) standard definitions. Congestive heart failure (CHF)
was defined as either paroxysmal nocturnal dyspnea,
dyspnea on exertion due to CHF, a chest x-ray showing
pulmonary congestion or pedal edema and dyspnea and
receiving diuretics or digoxin within two weeks prior to
the surgical procedure. Use of ASA, ACE-inhibitors or sta-
tins was defined as whether the patient received the medi-
cation within 24 hours prior to surgery. Diabetes mellitus
indicated whether the patient had a history of diabetes,
regardless of duration or need for anti-diabetic agents.
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teria included the documentation of total cholesterol >
200 mg/dl or LDL > 130 mg/dl or HDL < 30 mg/dl or
admission cholesterol > 200 mg/dl or triglycerides > 150
mg/dl. The criteria for hypertension included a documen-
ted history of hypertension diagnosed and treated with
medication/diet and/or exercise, blood pressure > 140 sys-
tolic or > 90 diastolic on at least two occasions or cur-
rently on antihypertensive medication.
Definition of perioperative acute kidney injury (AKI) and
in-hospital mortality
Perioperative AKI was defined according to the criteria of
The Society of Thoracic Surgeons (STS) as an increase in
creatinine > 2.0 (mg/dl), a 100% increase from the most
recent preoperative creatinine level, or need for dialysis
[15]. In-hospital mortality was defined as death occurring
during the hospitalization in which the original cardiac
surgical intervention was performed, according to STS
standards [15].
Identification of DTA atheroma
The institutional intraoperative TEE database was used to
identify cardiac surgical patients in whom imaging win-
dows of the descending thoracic aorta were obtained. Off-
line analysis of the recorded study was performed, and the
degree of DTA atheroma was independently assessed by
two attending cardiac anesthesiologists certified in perio-
perative TEE. Data from the thoracic aorta were extracted
from the comprehensive TEE examination that is
performed as part of routine care in applicable cardiac sur-
gery patients. The following views were reviewed in accor-
dance with the published Society of Cardiovascular
Anesthesiologists/American Society of Echocardiography
guidelines:
Descending Aorta:
1. Midesophageal descending aorta short axis at 0
degrees
2. Midesophageal descending aorta short axis at 90
degrees.
The severity of DTA atheroma was graded according to
the practice guidelines for perioperative transesophageal
echocardiography. A report by the American Society of
Anesthesiologists and the Society of Cardiovascular
Anesthesiologists Task Force on Transesophageal Echo-
cardiography defines the grades as follows: [16] Grade 1 =
no calcification, Grade 2 = intimal thickening ≤1m m ,
Grade 3 = calcific protrusion 1 to 5 mm into the aortic
lumen, Grade 4 = calcific protrusion > 5 mm into aortic
lumen, Grade 5 = mobile atheroma. For this study, we
defined significant DTA atheroma as the presence of an
intraluminal plaque > 1 mm (that is, Grades 3 to 5 as
described above) [17].
Statistical analysis
Descriptive statistics were obtained on patient characteris-
tics including demographic data, past medical history and
in-hospital data. For bivariate analysis the Fishers exact
test for the categorical variables and the non-parametric
Mann-Whitney U test for the continuous variables were
employed. Multivariate analysis was performed using
logistic regression. Covariates adjusted for included all the
variables that had a P
30.2 or that were felt to be clinically
significant confounders. The Wald statistic was used to
define the significance of the regression coefficients. A
backward stepwise (likelihood ratio) technique was used
for the multivariate analysis. The OR, P values and 95% CI
were obtained from this. A P value of 0.05 was used to
reject the null hypothesis (that the regression coefficient
equates to zero). The statistical analysis was performed
using JMP (Cary, NC, USA) and SPSS (Chicago, IL, USA).
Results
Patient characteristics and surgical procedures
Demographic data did not differ significantly between
groups (Table 1) except for patients in the +DTA group
who were slightly older and less likely to be men. Diabetes
mellitus was more prevalent in the patient groups with
calcification of the DTA, but this difference was not statis-
tically significant. The use of preoperative drug therapy
was not significantly different between groups (Table 1).
Surgical procedures performed were not statistically differ-
ent between groups (Table 2). The use of antifibrinolytics
such as amicar (ε-aminocaproic acid) or aprotinin did not
differ between groups and was not an independent predic-
tor of AKI or death in our patient population (Table 2).
AKI and in-hospital mortality
The total incidence of AKI was 6.4% within the study
population. The analysis showed that 3.9% of the patients
without IABP support developed AKI compared with 8.8%
of the patients with IABP. The incidence and the ORs of
AKI within groups were as follows: -DTA atheroma/-
IABP: 1.7%, -DTA atheroma/+IABP: 5.1%, +DTA ather-
oma/-IABP: 5.5%, and +DTA atheroma/+IABP: 12.6%.
Using Fisher’s exact test, patients with the combination of
IABP and DTA atheroma (+IABP/+DTA atheroma) had a
significantly increased risk of developing postoperative
AKI (P = 0.0016, relative risk increase 7.062, CI = 1.64 to
30.4) when compared to patients without IABP and with-
out DTA atheroma (-IABP/-DTA atheroma). Patients
with either IABP or DTA atheroma showed an increase in
AKI postoperatively, which was not statistically significant
when compared to either group (Figure 1).
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operative AKI were more likely to be older than 65 years
(P = 0.008); have a history of CHF (P = 0.026), undergoing
a valve procedure (P = 0.012) and have DTA calcification
(P = 0.003) or an IABP (P = 0.002) (Table 3). Multivariate
logistic regression controlling for confounders such as
patient demographics, preoperative risk factors, medica-
tions and intraoperative variables demonstrated a history
of CHF (P = 0.026, OR = 2.81, CI = 1.13 to 6.97), the use
of IABP (P = 0.015, OR = 3.04, CI = 1.24 to 7.45) and
DTA calcification (P = 0.002, OR = 4.13, CI = 1.66 to
10.30) as independent predictors for the development of
AKI in our patient population (Table 4). An analysis of
effects (the chi-square test statistics and associated
P-values) indicates that IABP and calcification are signifi-
cantly associated with increased postoperative AKI indivi-
dually, but not the interaction between the two.
The incidence of in-hospital mortality among all
patients was 11.3% and included 6.6% of patients with-
out an IABP versus 16.2% of patients with IABP sup-
port. The incidence of in-hospital mortality by Group
was: -DTA atheroma/-IABP: 3.4%, -DTA atheroma/
+IABP: 8.5%, +DTA atheroma/-IABP: 6.4%, and +DTA
atheroma/+IABP: 20.2%.
Using Fisher’s exact test, patients with the combina-
tion of IABP and DTA atheroma (+IABP/+DTA ather-
oma) had a significantly increased risk of increased
postoperative mortality (P = 0.0001, relative risk increase
5.7, CI = 2.04 to 15.9) when compared to patients with-
o u tI A B Pa n dw i t h o u tD T Aa t h e r o m a( - I A B P / - D T A
atheroma) (Figure 2).
In the univariate analysis, patients who died were more
likely to be older than 65 years (P = 0.008), have a history
of CHF (P = 0.01), receiving either aminocaproic acid (P =
0.04) or aprotinin (P = 0.041) and have DTA calcification
(P = 0.04) or an IABP (P =0 . 0 3 6 )( T a b l e3 ) .M u l t i v a r i a t e
logistic regression controlling for confounders such as
patient demographics, preoperative risk factors, medica-
tions and intraoperative variables showed age (P = 0.015,
OR = 3.53, CI = 1.28 to 9.75), perfusion time (P =0 . 0 0 2 ,
OR = 1.01, CI = 1.00 to 1.01), the use of an IABP (P =
0.016, OR = 2.61, CI = 1.19 to 5.70) and DTA calcification
Table 1 Demographic data, preoperative co-morbidities and medications stratified by the presence of DTA atheroma
and IABP support.
Group -DTA/-IABP
(Number = 114)
-DTA/+IABP
(Number = 114)
+DTA/-IABP
(Number = 113)
+DTA/+IABP
(Number = 113)
Age in years
(Mean ± SD)
65/± 13.7 65/± 11.8 71/± 11.2 71.4/± 9.7
Male 72 (63.0%) 66 (57.6%) 61 (53.9%) 64 (56.6%)
Female 42 (36.0%) 48 (42.4%) 52 (46.0%) 49 (42.9%)
HTN 74 (62.2%) 81 (68.6%) 75 (70.8%) 87 (79.8%)
DM 32 (26.9%) 31 (26.3%) 47 (44.3%) 46 (42.2%)
HCL. 80 (67.2%) 83 (70.3%) 78 (73.6%) 82 (75.2%)
ACE 74 (62.2%) 50 (42.3%) 63 (59.4%) 64 (58.7%)
ASA 86 (72.3%) 76 (64.4%) 77 (72.6%) 86 (78.9%)
Statins 76 (63.9%) 67 (56.8%) 68 (64.1%) 67 (61.5%)
LVEF (%) 41.4/± 15.6 43.0/± 15.3 39.6/± 15.4 38.6/± 15.1
CHF 41 (34.5%) 57 (48.3%) 45 (42.5%) 64 (58.7%)
ACE, angiotension converting enzyme inhibitors; ASA, aspirin; CHF, congestive heart failure; DM, diabetes mellitus; HCL, hypercholesterolemia; HTN, hypertension;
LVEF, left ventricular ejection fraction; Statins, HMGCoA reductase inhibitors.
Table 2 Intraoperative variables and anti-fibrinolytics stratified by the presence of DTA atheroma and IABP support.
Group -DTA/-IABP
(Number = 114)
-DTA/+IABP
(Number = 114)
+DTA/-IABP
(Number = 113)
+DTA/+IABP
(Number = 113)
CABG
a 67 (58.70%) 68 (59.6%) 59 (52.2%) 60 (53.1%)
Valve
b 14 (12.2%) 16 (14.0%) 14 (12.4%) 13 (11.5%)
CABG and Valve
c 29 (25.4%) 26 (22.8%) 37 (32.7%) 37 (32.7%)
Others
d 4 (3.5%) 4 (3.5%) 3 (2.6%) 3 (2.7%)
CPB time in min (Mean ± SD) 137 ± 99.5 142 ± 73.6 150.2 ± 78.4 174.8 ± 82.1
CX time in min (Mean ± SD) 95.9 ± 45.9 91.8 ± 44.7 109 ± 56.7 110.9 ± 55.6
Amicar 96 (84.2%) 93 (81.5%) 91 (80.5%) 93 (82.3%)
Aprotinin 18 (15.7%) 21 (18.4%) 22 (19.5%) 20 (17.7%)
aincludes primary and reoperation;
b, cprimary, ReOp and double valves;
dLVA repair, heart transplant, TMLR, Ascending Aorta repair, VSD repair.
CABG, coronary artery bypass graft; CPB time, cardio-pulmonary bypass time; CX time, cross-clamp time; SD, standard deviation
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dent risk factors for mortality (Table 5).
An analysis of effects (the chi-square test statistics and
associated P-values) indicates that IABP and calcification
are significantly associated with in-hospital mortality
individually, but not the interaction between the two.
Discussion
Postoperative AKI remains a severe complication follow-
ing cardiac surgery, and is associated with a prolonged
hospital stay and an increased risk for in-hospital mor-
tality [18-20]. The etiology of postoperative AKI has
been attributed to embolic events, inflammation, ische-
mia-reperfusion injury, intravenous contrast and a vari-
ety of medications [20,21]. In addition, the use of an
IABP has been associated with an increase in the risk of
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Figure 1 Incidence of perioperative acute kidney injury (AKI) in the presented study population. DTA, descending thoracic aortic
atherosclerosis; IABP, intraaortic balloon counterpulsation.
Table 3 Univariate analysis stratifying the risk for acute
kidney injury (AKI) and in-hospital mortality (Number =
454).
AKI
(P-value)
Mortality
(P-value)
DTA calcification 0.003* 0.04*
IABP 0.002* 0.036*
LV dysfunction 0.37 0.179
ACE inhibitors 0.88 1.0
ASA 0.63 0.53
Statin 0.23 0.34
Age (> than 65 years) 0.008* 0.04*
DM 0.07 1.0
HTN 0.10 0.40
CHF* 0.026* 0.01*
Cardiogenic shock 0.13 0.07
CX time 0.20 0.024*
CPB time 0.11 0.001*
Aprotinin 0.04 0.83
Aminocaproic Acid 0.04 0.83
* statistically significant (P < 0.05)
ACE, angiotension converting enzyme inhibitors; ASA, aspirin; CHF, congestive
heart failure; CX time, cross-clamp time; DM, diabetes mellitus; DTA,
descending thoracic aorta; HTN, hypertension; IABP, intra-aortic balloon pump;
LV dysfunction, left ventricular dysfunction; LVEF, left ventricular ejection
fraction; Statins, HMGCoA reuctase inhibitors.
Table 4 Independent predictors of postoperative Acute
Kidney Injury (AKI) by multivariate analysis (Number = 454).
P-value OR 95% CI
DTA calcification *0.002 4.13 1.66-10.30
IABP *0.015 3.04 1.24-7.45
CHF *0.026 2.81 1.13-6.97
CHF, congestive heart failure; CI, confidence interval; DTA, descending thoracic
aorta; IABP, intra-aortic balloon pump; OR, odds ratio.
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an IABP in providing perioperative circulatory support
must be weighed against the potentially lethal complica-
tion of AKI in critically ill patients [22-24]. We now
confirm that DTA atheroma is a risk factor for the
development of perioperative AKI in cardiac surgery
patients. Moreover, we also show that the combined
presence of DTA atheroma and IABP significantly
increases the risk of perioperative AKI in-hospital mor-
tality when compared to control subjects without IABP
and without significant DTA atheroma. Adding an IABP
to a patient population with already severe DTA ather-
oma did not increase the overall risk for AKI and/or
mortality significantly.
Aortic atheroma has been previously linked to post-
operative renal injury. MacKensen et al. showed that
ascending aortic atheroma is an independent risk factor
for postoperative renal failure [21]. In their study, des-
cending aortic atheroma alone did not demonstrate an
increased risk for postoperative renal injury. In addition,
atheroma of the aorta has also been associated with an
increased incidence of perioperative adverse outcomes
including stroke, multiorgan failure and death [25,26].
The degree, mobility and location of aortic atheroma are
associated with an increased risk for systemic emboliza-
tion and cerebral stroke [11-14]. Intraoperative TEE has
become the standard imaging modality for identifying
aortic atheroma and influencing therapy in 8% to 17% of
cases [27]. Katz et al. showed that aortic arch artheroma,
assessed intraoperatively with TEE, was the only variable
to predict cerebral embolic events after cardiac surgery
[17,27]. However, prior studies evaluating the risk of AKI
in patients undergoing surgery with and without the use
of an IABP have not included an evaluation and measure-
ment of DTA atheroma severity.
The exact mechanism of IABP-induced aortic damage
remains unclear. Tierney et al. demonstrated that the use
of an IABP can cause atheromatous lesions in the aorta to
rupture and cause fissures, even in the non-atheromatous
vessel [28], which is in keeping with our initial hypothesis
that dislodged atheromatous material can lead to down-
ward stream embolization of renal vessels when using
IABP support. Ramnarine et al. demonstrated that the use
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Figure 2 Incidence of perioperative mortality in the presented study population. DTA, descending thoracic aortic atherosclerosis; IABP,
intraaortic balloon counterpulsation.
Table 5 Independent predictors of postoperative
Mortality by multivariable analysis (Number = 454).
P-value OR 95% CI
DTA calcification *0.012 2.69 1.24-5.83
IABP *0.016 2.61 1.19-5.70
Age *0.015 3.53 1.28-9.75
Perfusion time * < 0.002 1.01 1.00-1.01
CI, confidence interval; DTA, descending thoracic aorta; IABP, intra-aortic
balloon pump; OR, odds ratio.
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death in a heterogeneous population (isolated coronary
artery bypass grafting (CAGB) and valve procedures, as
well as combined CABG and valve procedures) of more
than 7,600 patients [6]. Those patients who required IABP
in this study were generally older, had preoperative renal
dysfunction and severely decreased LV function. In a large
prospective study of over 43,000 cardiac surgical patients
Chertow et al. found that the preoperative use of IABP
was an independent risk factor for postoperative AKI (OR:
4.57; 95% CI 3.57 to 5.86) [20]. However, the overall inci-
dence of AKI in this patient population was only 1.1%,
since only patients who required dialysis were included in
the analysis of postoperative AKI. In another study of
2,672 patients undergoing CABG, 7.9% of patients devel-
oped AKI and 0.7% of patients required postoperative dia-
lysis [8]. Recently, Wijeysundera et al. also demonstrated
that the pre-operative placement of an IABP significantly
increased the risk for AKI in a heterogeneous group of
cardiac surgical patients [29]. None of these previous
investigations included DTA atheroma as a variable in the
analysis of perioperative morbidity and mortality. Fabbian
et al. were able to link the degree of aortic calcification
with renal failure. In their retrospective analysis, they
assessed the presence of aortic arch calcification examined
by chest radiography and the incidence of dialysis-depen-
dent chronic renal failure [30]. Davila-Roman et al. could
link ascending aortic artherosclerosis with the develop-
ment of acute renal injury after CABG surgery [10]. In
their prospective study they investigated 978 patients and
used epiaortic echocardiography of the ascending aorta as
a surrogate marker for DTA atheroma.
While our study provides novel insight into the influence
of DTA atheroma and IABP on the incidence of AKI and
mortality following cardiac surgery, certain limitations are
worth noting including the use of a retrospective evalua-
tion and a relatively small number of patients. While a pro-
spective study involving a randomized assignment to the
use of an IABP in a large, multicenter investigation might
be ideal, the ethical limitations and purported clinical bene-
fit of IABP in high risk populations would significantly
restrict its feasibility. Furthermore, in our population,
patients with significant DTA atheroma were also more
likely to be older and have lower LVEF with CHF.
We attempted to statistically control for these potential
confounders, which ultimately allowed us to demonstrate
significant associations between DTA and IABP with AKI.
We also acknowledge that our assessment of renal injury
using postoperative peak serum creatinine levels as the
only marker is controversial and not perfect; however, it is
commonly used in the clinical setting. The addition of
creatinine clearance data or novel biomarkers such as
NGAL might have been beneficial, but could not be
obtained due to the retrospective nature of this study [31].
Conclusions
In summary, the results of our study highlight the
importance of the independent and interdependent
influence of DTA atheroma and IABP support on perio-
perative AKI and mortality following cardiac surgery.
Unfortunately, we were not able to show a clear inde-
pendent association that the combination of IABP and
DTA atheroma causes an increase of AKI and/or in-hos-
pital mortality in cardiac surgical patients. We were able
to show though that the combination of IABP and DTA
atheroma increases AKI and in-hospital mortality when
compared to patients without IABP or DTA disease.
Further larger studies are needed to clarify this clinically
important question.
While the risk benefit ratio of IABP counterpulsation
may still be favorable in patients regardless of the pre-
sence of DTA atheroma, identifying the severity and
exact location of aortic atheroma, may be useful for risk
stratification, directing optimal positioning of an IABP
under echocardiographic guidance, or influencing the
decision to utilize alternative sites for IABP placement
including nonconventional transbrachial techniques [32].
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balloon counterpulsation; IRB: Institutional Review Board; LDL: low density
lipoprotein; LVEF: left ventricular ejection fraction; OR: odds ratio; SD:
standard deviation; STS: society of thoracic surgeons; TEE: transesophageal
echocardiography.
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